Skip to content
HowShorted

MYRIAD GENETICS INC short interest in 2018

In 2018, MYRIAD GENETICS INC's disclosed short interest ran from 19.14% of shares outstanding on 12 Jan 2018 to 18.56% on 31 Dec 2018, a change of -0.58 percentage points. The year's high was 19.87% on 15 May 2018 and its low 14.11% on 28 Sep 2018, averaging 17.03% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.00 days on 30 Apr 2018. Full history: MYRIAD GENETICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MYRIAD GENETICS INC in 2018

2018 in figures

Start of year
19.14% (12 Jan 2018)
End of year
18.56% (31 Dec 2018)
Change
-0.58 pp
High
19.87% (15 May 2018)
Low
14.11% (28 Sep 2018)
Average
17.03%
Highest days to cover
29.00 (30 Apr 2018)
SEC filings marked
8

Every report in 2018

MYRIAD GENETICS INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201819.14%25.92
31 Jan 201818.70%14.45
15 Feb 201818.41%14.41results (8-K), 10-Q filed
28 Feb 201818.14%24.79
15 Mar 201818.70%17.34
29 Mar 201818.60%18.47
13 Apr 201819.70%18.76
30 Apr 201819.81%29.00
15 May 201819.87%16.26results (8-K), 10-Q filed
31 May 201818.14%20.16
15 Jun 201816.95%17.40
29 Jun 201815.18%11.22
13 Jul 201815.69%12.06
31 Jul 201814.16%13.66
15 Aug 201814.22%15.69
31 Aug 201814.60%10.80results (8-K), 10-K filed
14 Sep 201814.51%15.38
28 Sep 201814.11%15.96
15 Oct 201814.17%13.10
31 Oct 201816.87%15.79
15 Nov 201816.41%7.18results (8-K), 10-Q filed
30 Nov 201816.92%14.20
14 Dec 201817.21%14.75
31 Dec 201818.56%14.69

See also: MYRIAD GENETICS INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.